Inclusion Criteria:
- Primary CNS lymphoma diagnosed histologically or by cerebrospinal fluid cytology;
absence of systemic lymphoma manifestations
- Relapse or lymphoma progression after/during high-dose methotrexate containing
first-line chemotherapy or alternative therapy in the case of contraindications
against high-dose methotrexate
- ECOG performance score ≤ 2
- Age ≥18 years and ≤ 75 years
- Life expectancy of at least 3 months
- Absence of active infection
- Negative HIV serology
- Adequate renal function (GFR >30ml/h)
- Adequate bone marrow reserve (neutrophils > 1500/µl, platelets > 80,000/µl)
- Bilirubin <1.5x upper limit of normal (ULN), ALT and AST <3x ULN
- At least 3 weeks interval from prior cytostatic treatment
- Negative pregnancy test
- Patient accessible for treatment and follow-up
- Patient compliance
- Signed informed consent
Exclusion Criteria:
- Secondary CNS lymphoma
- Primary intraocular lymphoma
- Patient eligible for high-dose chemotherapy and autologous stem-cell transplantation
- Concurrent treatment within another clinical trial
- Concurrent other malignant disease
- Symptomatic congestive heart failure (≥NYHA II)
- Active or uncontrolled chronic infection
- Severe concomitant disease incompatible with study conduct
- History of cerebral bleeding
- Concomitant treatment with strong CYP3A4/5-inductors or -inhibitors
- Premenopausal women without highly effective contraception (defined as Pearl index
<1)
- Pregnant or lactating women
- Refusal to record and pass on pseudonymized disease and treatment related data as
part of the treatment protocol
- Concurrent admission to a psychiatric institution by public order